Skin Microbiome in Patients with Hand Eczema and Healthy Controls: A Three-week Prospective Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 2,39 MB, PDF-dokument

  • Line Brok Nørreslet
  • Berit Lilje
  • Anna Cäcilia Ingham
  • Sofie Marie Edslev
  • Maja-Lisa Clausen
  • Frederik Plum
  • Paal Skytt Andersen
  • Agner, Tove

The pathogenesis of chronic hand eczema remains un-clear. Insights into the skin microbiome in hand eczema and its potential relevance to disease severity may help to elucidate the underlying mechanisms of hand eczema. The aim of this study was to characterize the microbiome in patients with hand eczema and healthy controls. A 5-visit prospective study was conducted over a period of 3 weeks. At each visit, bacterial swabs were taken from the hands of patients with hand eczema and controls. The microbiome was examined using DNA extraction and 16S rRNA amplicon sequencing (V3–V4 regions). Fifty patients with hand eczema and 50 controls were included (follow-up rate=100%). The baseline bacterial α-diversity was reduced on the hands of patients with hand eczema compared with controls (effect size=–0.31; 95% confidence interval (95% CI) –0.50; –0.11; p = 0.003). The dysbiosis on the patients’ hands was stable over the study period, was associated with disease severity, and was characterized by reduced bacterial diversity and different bacterial community compositions.

OriginalsprogEngelsk
Artikelnummeradv00633
TidsskriftActa Dermato-Venereologica
Vol/bind102
Antal sider7
ISSN0001-5555
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
The data for this study have been deposited in the European Nucleotide Archive (ENA) at EMBL-EBI under accession number PRJEB46105 (https://www.ebi.ac.uk/ena/browser/view/ PRJEB46105). Role of the funding source: The funding source had no influence on study design, the collection, analysis and interpretation of data; the writing of the manuscript; or the decision to submit the article for publication. Funding: Grants from The Danish Working Environment Research Fund, Augustinusfonden, Aage Bangs Fund. Conflicts of interest: TA: Involved in advisory boards, consultant, lectures and clinical trials with Leo Pharma, Sanofi, Pfizer, Eli-Lilly and Abbvie. All other authors have no conflicts of interest to declare.

Publisher Copyright:
© 2022, Medical Journals/Acta D-V. All rights reserved.

ID: 312693886